Aspen Pharmacare Holdings (JSE:APN) Moat Score: 5/10 (As of Jul. 08, 2026)


JSE:APN Aspen Pharmacare Holdings Ltd JSE:APN
73 GF Score
Price R150.40
GF Value R178.04
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Aspen Pharmacare Holdings Moat Score?

Aspen Pharmacare Holdings JSE:APN -1.49% 73 Moat Score is 5 as of Jul. 08, 2026. GuruFocus rates JSE:APN with a GF Score™ of 73/100 and a GF Value™ of R178.04 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Aspen Pharmacare Holdings ranks better than 94.67% on this metric.

Aspen Pharmacare Holdings has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Aspen Pharmacare Holdings has Narrow Moat: Aspen Pharmacare has a solid narrow moat due to its strong brand in emerging markets and economies of scale in pharmaceutical manufacturing. However, it faces significant competition and lacks substantial regulatory barriers or unique intellectual property that would elevate it to a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Aspen Pharmacare Holdings might have Narrow Moat - Solid narrow moat.

Aspen Pharmacare Holdings  (JSE:APN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Aspen Pharmacare Holdings Moat Score Related Terms

JSE:APN vs ZTS, UTHR, VTRS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspen Pharmacare Holdings Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Aspen Pharmacare Holdings's Moat Score falls into.


JSE:APN
73GF Score
Aspen Pharmacare Holdings Ltd JSE:APN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Aspen Pharmacare Holdings (JSE:APN) has a Moat Score of 5 as of Jul. 08, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Aspen Pharmacare Holdings ranks #55 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Aspen Pharmacare Holdings' Moat Score too high?
Aspen Pharmacare Holdings' current Moat Score is 5. Based on the distribution chart, Aspen Pharmacare Holdings ranks #55 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Aspen Pharmacare Holdings has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aspen Pharmacare Holdings ranks #55 out of 1031 companies for Moat Score. This places Aspen Pharmacare Holdings in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Aspen Pharmacare Holdings's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (JSE:APN) is currently considered Modestly Undervalued. The stock's GF Value™ is R178.04, compared to a current price of R150.40 — trading 15.5% below its estimated fair value. The current Moat Score is 5. Aspen Pharmacare Holdings' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Aspen Pharmacare Holdings (JSE:APN), the current Moat Score is 5 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aspen Pharmacare Holdings (JSE:APN) Overvalued in 2026?

Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued. The current stock price of R150.40 is trading 15.5% below its estimated GF Value™ of R178.04. GuruFocus considers Aspen Pharmacare Holdings to be Modestly Undervalued.

Key valuation signals for JSE:APN:

  • Moat Score: 5
  • GF Value™: R178.04 vs. price of R150.40 (15.5% below fair value)
  • GF Score™: 73/100 with 10 warning signs

No single metric tells the full story. See the JSE:APN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aspen Pharmacare Holdings Business Description

Address Douglas Saunders Drive, Aspen Place, 9 Rydall Vale Park, La Lucia Ridge, Durban, NL, ZAF
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
73GF Score

Get the complete analysis for JSE:APN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R150.40
Price
R178.04
GF Value